Compositions and methods for inhibiting pathogen infection
AssigneeThe University of North Carolina at Chapel Hill
InventorsSamuel Lai, Bing Yang, Justin Mccallen
Life of this patent
Estimating the term…
Abstract
The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.
Claims28
A nebulized solution for treating or preventing Respiratory syncytial virus (RSV) in a subject inhaling the nebulized solution, the nebulized solution comprising a recombinant antibody having a human or humanized Fc region and an oligosaccharide having a glycosylation pattern that enhances the trapping potency of the recombinant antibody in mucus, so that the recombinant antibody binds to the RSV to form an antibody/RSV complex that is trapped in the subject's mucus thereby treating or preventing the infection, wherein the nebulized solution comprises particles having a mass median aerodynamic diameter (MMAD) of between 2-6 μm diameter and a concentration of antibody within the particles of between 10 mg/mL and 100 mg/mL.
A nebulized solution for treating or preventing Respiratory syncytial virus (RSV) in a subject inhaling the nebulized solution, the nebulized solution comprising a recombinant antibody against an epitope of the F protein of RSV, the recombinant antibody having a human or humanized Fc region and an oligosaccharide having a glycosylation pattern that enhances the trapping potency of the recombinant antibody in mucus, so that the recombinant antibody binds to the RSV to form an antibody/RSV complex that is trapped in the subject's mucus thereby treating or preventing the infection, wherein the nebulized solution comprises particles having a mass median aerodynamic diameter (MMAD) of between 2-6 μm diameter, a pH between 4.5 and 7, and a concentration of antibody within the particles of between 12 mg/mL and 100 mg/mL.
A nebulized solution for treating or preventing a respiratory virus in a subject inhaling the nebulized solution, the nebulized solution comprising a recombinant antibody having a human or humanized Fc region and an oligosaccharide having a glycosylation pattern that enhances the trapping potency of the recombinant antibody in mucus, so that the recombinant antibody binds to the respiratory to form an antibody/respiratory virus complex that is trapped in the subject's mucus thereby treating or preventing the infection, wherein the nebulized solution comprises particles having a mass median aerodynamic diameter (MMAD) of between about 2 and 6 μm diameter and a concentration of antibody within the particles of between 10 mg/mL and 100 mg/mL.
Dependencies are inferred from the claim text.